Indaptus Therapeutics, Inc.

NASDAQ:INDP

Biotechnology

Healthcare
$3.32 -2.21%

-$0.03 today

Market cap
$375.96M
Beta
1.14
P/E (TTM)
-0.2
EPS (TTM)
-$8.70
52W Low $0.92High $8.69

Volume 0.28M

Average 0.97M

Returns on capital

Indaptus Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-661.5%

avg -33.1%

ROIC

-629.3%

avg -16.7%

ROA

-223.9%

avg -110.6%

Analysis

ROA is currently the strongest return metric at -223.9% versus its period average of -110.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Junyi Dai

CEO & Chairman—3911.25M9.93%

Yu Ding

Chief Financial Officer—51——

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Mar 23, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

2

$0.00

Net Transaction Value

Neutral

Balanced transaction value

Most Active

Lazar David E.

2 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Mar 23, 26

Lazar David E.

Direct

Sell$0
Mar 23, 26

Lazar David E.

Direct

Sell$0

Summary

Insiders reported 0 buys worth $0.00 and 2 sells worth $0.00 over the last 12 months. Reported purchase and sale values were balanced. Lazar David E. was the most active insider with 2 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
N/A1 analysts
Net IncomeN/AN/AN/A
N/A1 analysts
EBITN/AN/AN/A
N/A1 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Indaptus Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Competitors

Peer companies in the same sector

Health

Questions

Management questions

Common questions about INDP's management, answered from reported figures.

Who manages INDP?

Indaptus Therapeutics, Inc. (INDP) lists 2 active executives. The top listed executive is Junyi Dai, CEO & Chairman.

Are INDP insiders buying or selling?

Recent insider activity shows net buying of $14.43M.